| Code | CSB-RA624104MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SSGJ-608, targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine central to immune responses and inflammatory disease pathogenesis. IL-17A is primarily produced by Th17 cells and plays a crucial role in host defense against extracellular pathogens by promoting neutrophil recruitment and activation. Dysregulated IL-17A signaling is implicated in numerous autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease. Elevated IL-17A levels contribute to chronic inflammation, tissue damage, and disease progression in these disorders.
SSGJ-608 represents a therapeutic antibody designed to neutralize IL-17A activity, making this biosimilar a valuable tool for investigating IL-17A-mediated pathways and inflammatory mechanisms. This antibody enables researchers to explore the role of IL-17A in disease models, evaluate potential therapeutic interventions, and study cytokine networks in autoimmune conditions. It serves as an essential reagent for immunology research, particularly in studies focused on Th17 cell biology and inflammation-related disorders.
There are currently no reviews for this product.